Cite
HARVARD Citation
Mohr, I. et al. (2023). Experience on switching trientine formulations in Wilson disease: Efficacy and safety after initiation of TETA 4HCl as substitute for TETA 2HCl. Journal of gastroenterology and hepatology. 38 (2), pp. 219-224. [Online].